| dc.description.abstract |
GTN refers to persistent or malignant disorders originating from the
abnormal proliferation of trophoblastic tissue, which may occur subse-
quent to a hydatidiform mole or a nonmolar pregnancy (Lurain, 2011).
An accurate determination of the global prevalence of GTN remains a
challenge due to inconsistencies in data reporting across different re-
gions. Analysis of cancer registries in Africa indicated an average inci-
dence of 0.38 cases per 100,000 women of reproductive age (Grimes,
1984) (Singh et al., 2021).
Patients diagnosed with GTN are typically categorized into risk
groups according to the prognostic scoring system established by the
World Health Organization (WHO): low risk (with a score of 0 to 6), high
risk (with a score of 7 to 12), and ultrahigh risk (with a score ≥ 13) (Figo
Oncology Committee, 2002). This system takes into account eight risk
factors that predict the potential for developing resistance to single-
agent chemotherapy with methotrexate (MTX) or actinomycin D (Act
D). Low-risk patients exhibit an almost 100 % overall survival (OS) rate,
whereas high-risk patients experience a survival rate ranging from 80 %
to 90 % (Lurain, 2011). A score of ≥ 13 is associated with a heightened
risk of early mortality, leading to recommendations for managing these
patients in highly specialized GTN centers. High-risk GTN cases often
originate from a normal pregnancy rather than a hydatidiform mole and
are frequently linked to lung metastases and, occasionally, metastases to
the brain and liver (Bolze et al., 2016).
Historically, prior to the introduction of effective chemotherapy
regimens, GTN was almost invariably fatal. However, advances in
chemotherapeutic agents for treatment have dramatically transformed
GTN into a highly curable disease.
Despite these advances in the management of GTN, the burden of
disease and outcomes from LMICs remain a concern, as mortality data
are sparse. The development of strategies for improving GTN care in this
setting is therefore a challenge. The inadequacies of healthcare infra-
structure and poor accessibility to specialized GTN care could contribute
to disparities in treatment outcomes in LMICs compared to those in the
Global North.
The objective of this study was to determine the proportion of
mortality in GTN patients and identify factors contributing to treatment
failure over a 10-year period at the second largest tertiary healthcare
facility in Kenya. This analysis seeks to highlight deficiencies in the
management of GTN within a low-resource setting and provide valuable
insights into areas requiring improvement. |
en_US |